An estrogen dependency for Menopause Consultants to examine

Endogenous estrogen after menopause

In 60 healthy postmenopausal women, depleting endogenous estrogen markedly reduced a growth-hormone rebound. The researchers used anastrozole to reduce estrogen and examined the GHRH-mediated release of growth hormone that followed a short intravenous somatostatin infusion. Low levels of endogenous estrogen still mattered to that response.

I expected depletion to tell the entire story. The rebound result shifted the emphasis toward influence that remains. The measured response concerned growth hormone, yet reducing estrogen changed it. The growth-hormone response needs an explanation that includes estrogen.

A consultant’s useful question here is what the response depends on. Sweeping talk of hormonal balance loses the particular dependency this experiment exposed.

Endogenous means produced within the body; here, the question concerned the estrogen already present.

A rebound after somatostatin

The sequence gives the postmenopausal experiment its interest: a short somatostatin infusion, followed by GHRH-mediated rebound growth-hormone secretion. Estrogen deprivation blunted that rebound. GHRH is growth hormone-releasing hormone, one of the signals regulating growth-hormone release.

I prefer this active test of the system to an inventory of hormone concentrations. The finding gives endogenous estrogen a functional role in the experiment, with a clearly defined response to examine.

The rebound study follows that sequence and places it alongside experiments in men, where the hormonal interventions and responses differed.

Tesamorelin and GHRH

Tesamorelin is a stabilised synthetic analogue of GHRH. That relationship makes the physiology relevant to the discussion around the peptide. It also requires some care: the estrogen-depletion study investigated a GHRH-mediated rebound, rather than demonstrating a benefit from tesamorelin in menopause.

The tesamorelin page follows the molecule's protective modification and a small hormone study in healthy men. The cognition page turns to a different question altogether: whether a change in this hormonal system translates into a measured cognitive benefit. The chemical modification and the cognitive outcome each have to earn their place.

Essay topics

• Estrogen and the rebound: the postmenopausal experiment and the influence of hormonal context.
• Tesamorelin's modification: protection against enzyme breakdown, followed by human hormone measurements.
• Cognitive outcomes: an executive-function result in older adults and a separate trial in people with HIV.

The articles are gathered on the reading list. About explains why this collection is called Menopause Consultants.